- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05024929
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Targeted Therapy to Increase RAI Uptake in Patients With Metastatic DifferentiatedThyroid Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Supriya Behl
- Phone Number: 267-426-9293
- Email: behls@chop.edu
Study Contact Backup
- Name: James Robinson
- Phone Number: 215-590-2053
- Email: robinsonj9@chop.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Not yet recruiting
- Boston Children's Hospital
-
Principal Investigator:
- JUNNE KAMIHARA, MD
-
Contact:
- Junne Kamihara, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Children's Hospital of Philadelphia
-
Contact:
- Supriya Behl
- Phone Number: 267-426-9293
- Email: behls@chop.edu
-
Principal Investigator:
- Theodore Laetsch, MD
-
Contact:
- James Robinson
- Phone Number: 215-590-2053
- Email: robinsonj9@chop.edu
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Contact:
- Steven Waguespack, MD
-
Principal Investigator:
- Steven Waguespack, MD
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Texas Children's Hospital
-
Contact:
- Priya Mahajan, MD
-
Principal Investigator:
- Priya Mahajan, MD
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Contact:
- Tyler Ketterl, MD, MS
-
Principal Investigator:
- Tyler Ketterl, MD, MS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria (Prospective Cohort):
- Patients with a histologic diagnosis of differentiated thyroid cancer
- Presence of an neurotrophic tyrosine kinase receptors (NTRK)-fusion, RET-fusion, anaplastic lymphoma kinase (ALK)-fusion, BRAF V600 mutation, BRAF-fusion or other targetable alteration identified in a Clinical Laboratory Improvement Amendments/College of American Pathologists (CLIA/CAP) laboratory
Anatomically evaluable disease on chest Computed tomography (CT) meeting oneo f the following criteria (obtained within 180 days of enrollment):
- multiple (10 or more) noncalcified solid pulmonary nodules visible on CT and/or
- enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease
Patients for whom systemic therapy with an oncogene-specific kinase inhibitor is planned from commercial supply or as part of a separate therapeutic clinical trial (that does not include data sharing with this protocol)/compassionate access protocol/single patient investigational new drug (IND). Such agents include, but are not limited to:
- Larotrectinib, entrectinib, selitrectinib, and repotrectinib for NTRK fusions
- Selpercatinib and pralsetinib for RET fusions
- Crizotinib, lorlatinib, repotrectinib, and alectinib for ALK fusions
- Dabrafenib and/or trametinib for BRAF V600 mutations
- Oncogene-specific kinase inhibitors other than those specifically delineated above must be approved by the overall study PI prior to enrollment
Inclusion Criteria (Data Sharing Cohort):
1. Patients enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing as part of the consent process for that trial.
Exclusion Criteria (All Cohorts):
- No prior oncogene-specific targeted therapy allowed. However, patients may enroll within 4 weeks of starting oncogene-specific therapy if a pre-therapy WBS is available. Prior therapy with non-oncogene specific multi-thyrosine kinase inhibitors (such as sorafenib, lenvatinib, and/or cabozantanib) is allowed.
- Females who are pregnant or breastfeeding are excluded due to the potential risks of the RAI used in the WBS to the fetus/neonate.
- Patients who require sedation/general anesthesia to complete a WBS are excluded.
- U.S. Military Personnel are excluded due to the Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) requirements.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prospective Cohort
Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial
|
Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND). During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor. |
Data Sharing Cohort
Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with increased tumor RAI-avidity after receiving oncogene-specific, targeted therapy
Time Frame: up to 5 years
|
The primary outcome measure is to determine the proportion of patients with differentiated thyroid cancer metastatic to the lungs for whom oncogene-specific, targeted therapy increases tumor RAI-avidity.
|
up to 5 years
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-018612
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Cancer
-
Emory UniversityNational Cancer Institute (NCI)Recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoSilicon Valley Community FoundationUnknownCancer | Pediatric CancerUnited States
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
Alexandria UniversityCompletedPediatric Cancer | Invasive CancerEgypt
-
University of California, San DiegoNational Cancer Institute (NCI); Dana-Farber Cancer Institute; University of... and other collaboratorsNot yet recruiting
-
Immune Oncology Research InstituteRecruitingContinuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With DexamethasonePediatric CancerArmenia
-
Connecticut Children's Medical CenterThe Hospital for Sick ChildrenRecruitingPediatric CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingPediatric CancerUnited States
-
Erin RowellRecruiting
-
Giselle ShollerRecruiting
Clinical Trials on Whole body scan
-
Assaf-Harofeh Medical CenterUnknownInjuries and Wounds
-
University College London HospitalsRecruitingArthritis, Juvenile Idiopathic | Enthesitis-Related Arthritis, JuvenileUnited Kingdom
-
Ontario Clinical Oncology Group (OCOG)Ontario Ministry of Health and Long Term CareCompletedAdenocarcinoma | Cervical Cancer | Squamous Cell Carcinoma | Adenosquamous CarcinomaCanada
-
University Health Network, TorontoProstate Cancer CanadaCompleted
-
Centennial Medical GroupTerminatedHealth BehaviorUnited States
-
Molecular Insight Pharmaceuticals, Inc.CompletedProstate CancerUnited States, Canada
-
King's College Hospital NHS TrustKing's College LondonNot yet recruitingCritical Illness | Thrombosis | Ascites | Pleural Effusion | Cardiac Complication | ConsolidationUnited Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
Gazi UniversityGulhane Training and Research HospitalRecruitingArthropathy of Knee | Whole-body Vibration | Swelling/ EdemaTurkey
-
Federal University of Health Science of Porto AlegreCompletedChronic Obstructive Pulmonary DiseaseBrazil